Niagen Bioscience, Inc. (NASDAQ: NAGE) is a research-driven biotech firm dedicated to the development and commercialization of nicotinamide adenine dinucleotide (NAD⁺) boosting compounds and related nutraceuticals. Founded in 2016 and headquartered in Irvine, California, the company traces its origins to academic research in cellular metabolism and longevity. Since its inception, Niagen Bioscience has pursued a mission to translate early‐stage discoveries into scalable products that support cellular health, with a particular emphasis on age‐related metabolic and neurological conditions.
The company’s flagship product is a proprietary formulation of nicotinamide riboside (NR), a vitamin B3 derivative shown to increase intracellular NAD⁺ levels. In addition to direct‐to‐consumer offerings through its online platform, Niagen Bioscience supplies bulk NR ingredients to dietary supplement manufacturers and partners with contract research organizations for clinical studies. Its R&D pipeline features next‐generation NAD⁺ precursors and co-formulations designed to address mitochondrial dysfunction, muscle performance, and cognitive support.
Niagen Bioscience serves a global market, distributing its products across North America, Europe, and the Asia-Pacific region. The company has established strategic collaborations with universities, biotech firms, and international distribution partners to expand its geographic footprint and accelerate product registration in key regulatory jurisdictions. Through these alliances, it aims to advance clinical programs and navigate evolving regulatory pathways for wellness and therapeutic applications of NAD⁺ modulation.
Governance at Niagen Bioscience is led by a management team with extensive experience in biotechnology and nutraceutical commercialization. The executive leadership includes CEO Frank Jaksch, a pioneer in nutritional sciences, alongside a board of directors and scientific advisory panel drawn from academia and industry. Moving forward, the company intends to bolster its clinical development efforts, enhance manufacturing scale-up, and explore new indications for its NAD⁺‐enhancing platform.
AI Generated. May Contain Errors.